Adapting Products to the Unique and Evolving Needs of the CGT Industry with OriGen Biomedical

1 November 2021
Employing a Customer Driven Product Development Process to adapt products to CGT protocols.

PLAY VIDEO ABOVE * OriGen Biomedical, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.

For this technology demonstration, David Miller, Senior Sales Manager and Nathan Thompson, Director of Engineering at OriGen Biomedical explain the process for adapting cell and gene therapy products to specific customer needs, recommending that through the ‘Customer Driven Product Development Process’, a product can be adapted rather than the protocol.

After explaining the different steps of the process, the pair go on to explain the process within the context of a case study for the development of the CS50V7, and describe how standard cell and gene therapy products can be integrated into automated platforms.

Phacilitate member? Watch this video and join the conversation via the network.

Not yet a member?
Join Today.